DOCSLIB.ORG

Ep 2308965 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ep 2308965 A1 (19) & (11) EP 2 308 965 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.04.2011 Bulletin 2011/15 C12N 9/04 (2006.01) C12P 7/60 (2006.01) C12P 17/04 (2006.01) (21) Application number: 10183907.4 (22) Date of filing: 10.02.2006 (84) Designated Contracting States: (71) Applicant: DSM IP Assets B.V. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 6411 TE Heerlen (NL) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (72) Inventors: • Beuzelin Ollivier, Marie-Gabrielle (30) Priority: 11.02.2005 EP 05405066 1131 Tolochenaz (CH) 11.02.2005 EP 05405067 • Chevreux, Bastien 11.02.2005 EP 05405072 79618, Rheinfelden (DE) 11.02.2005 EP 05405073 • Dalluegge, Manuela 11.02.2005 EP 05405081 79618, Rheinfelden (DE) 11.02.2005 EP 05405082 • Gelder Van, Marina 11.02.2005 EP 05405083 3205, TG Spijkenisse (NL) 11.02.2005 EP 05405084 • Goese, Markus G. 11.02.2005 EP 05405087 4054, Basel (CH) 11.02.2005 EP 05405088 • Hauk, Corina 11.02.2005 EP 05405089 79576 Weil am Rhein (DE) 11.02.2005 EP 05405090 • Koekman, Bertus Pieter 11.02.2005 EP 05405091 2636 BG Schipluiden (NL) 11.02.2005 EP 05405093 • Meury Bechtel, Anja 11.02.2005 EP 05405094 8032 Zürich (CH) 11.02.2005 EP 05405109 • Mouncey, Nigel John 11.02.2005 EP 05405110 Indiananpolis, IN 46220 (US) 11.02.2005 EP 05405111 • Mayer, Anne Françoise 11.02.2005 EP 05405112 4052 Basel (CH) 11.02.2005 EP 05405119 • Schipper, Dick 11.02.2005 EP 05405120 2612 HL Delft (NL) 11.02.2005 EP 05405121 • Toepfer, Christine 11.02.2005 EP 05405139 79630 Murg (DE) 11.02.2005 EP 05405140 • Vollebregt, Adrianus Wilhelmus Hermanus 11.02.2005 EP 05405146 2673 BB Naaldwijk (NL) 11.02.2005 EP 05405147 • Lee, Connie 11.02.2005 EP 05405148 107 Reykjavik (IS) 11.02.2005 EP 05405149 • Shinjoh, Masako 11.02.2005 EP 05405150 Kamakura Kanagawa 248-0017 (JP) 11.02.2005 EP 05405151 11.02.2005 EP 05405152 (74) Representative: Seibel-Thomsen, Nadja 11.02.2005 EP 05405153 DSM Nutritional Products Ltd 11.02.2005 EP 05405166 Patent Department 11.02.2005 EP 05405167 Wurmisweg 576 11.02.2005 EP 05405168 4303 Kaiseraugst (CH) 11.02.2005 EP 05405169 11.02.2005 EP 05405170 Remarks: This application was filed on 30-09-2010 as a (62) Document number(s) of the earlier application(s) in divisional application to the application mentioned accordance with Art. 76 EPC: under INID code 62. 06706841.1 / 1 846 554 EP 2 308 965 A1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 308 965 A1 (54) Fermentative vitamin C production (57) The present invention relates to newly identified pact on yield, production, and/or efficiency of production microorganisms capable of direct production of L- ascor- of the fermentation product in said microorganism. Also bic acid (hereinafter also referred to as Vitamin C). The included are methods/processes of using the polynucle- invention also relates to polynucleotide sequences com- otides and modified polynucleotide sequences to trans- prising genes that encode proteins which are involved in form host microorganisms. The invention also relates to the synthesis of Vitamin C. The invention also features genetically engineered microorganisms and their use for polynucleotides comprising the full length polynucleotide the direct production of Vitamin C. sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equiv- alents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnolog- ical tools in the production of Vitamin C from microorgan- isms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect im- 2 EP 2 308 965 A1 Description [0001] The present invention relates to the use of polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby said polynucleotides and/or encoded polypeptides have a direct 5 or indirect impact on yield, production, and/or efficiency of production of the fermentation product. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C. [0002] Vitamin C is one of very important and indispensable nutrient factors for human beings. Vitamin C is also used in animal feed even though some farm animals can synthesize it in their own body. [0003] For the past 70 years, Vitamin C has been produced industrially from D- glucose by the well-known Reichstein 10 method. All steps in this process are chemical except for one (the conversion of D- sorbitol to L-sorbose), which is carried out by microbial conversion. Since its initial implementation for industrial production of Vitamin C, several chemical and technical modifications have been used to improve the efficiency of the Reichstein method. Recent developments of Vitamin C production are summarized in Ullmann’s Encyclopedia of Industrial Chemistry, 5th Edition, Vol. A27 (1996), pp. 547ff. 15 [0004] Different intermediate steps of Vitamin C production have been performed with the help of microorganisms or enzymes isolated therefrom. Thus, 2-keto-L-gulonic acid (2-KGA), an intermediate compound that can be chemically converted into Vitamin C by means of an alkaline rearrangement reaction, may be produced by a fermentation process starting from L-sorbose, by means of strains belonging e.g. to the Ketogulonicigenium or Gluconobacter genera, or by an alternative fermentation process starting from D-glucose, by means of recombinant strains belonging to the Glucono- 20 bacter or Pantoea genera. [0005] Current chemical production methods for Vitamin C have some undesirable characteristics such as high- energy consumption and use of large quantities of organic and inorganic solvents. Therefore, over the past decades, other approaches to manufacture Vitamin C using microbial conversions, which would be more economical as well as eco- logical, have been investigated. 25 [0006] Fermentative Vitamin C production from a number of substrates including D- sorbitol,L- sorbose and L- sorbosone has been reported in several microorganisms, such as algae and yeast, using different cultivation methods. The disad- vantage of using these microorganisms, however, is the low yield of Vitamin C produced since thes organisms are known to be capable of the production of both 2-keto-L-gulonic acid and Vitamin C, the yield of microbiologically produced Vitamin C is then limited by the relatively high production of 2-KGA which is more readily synthesized by said microor- 30 ganism, leading, for instance, to ratios between the concentration of Vitamin C and 2-KGA which are less than 0.1. [0007] Therefore it is desirable to develop production systems which have better industrial applicability, e.g. can be manipulated for increased titers and/or which have reduced fermentation times. One particularly useful system employs genes encoding membrane-bound L-sorbosone dehydrogenases or membrane-bound PQQ bound D- sorbitol dehydro- genases. An example of such a system uses a gene from Gluconobacter oxydans N44-1 encoding L-sorbosone dehy- 35 drogenase (hereafter called SNDHai) which converts L- sorbosone to L- ascorbic acid. This gene and homologous thereof have already been described in WO 2005/017159 which are incorporated herein. [0008] There is a continuing need in even more optimized fermentation systems for the microbial production of Vitamin C to get higher yields as with the systems described above. [0009] Surprisingly, it has now been found that under suitable culture conditions host cells expressing SNDHai can 40 be used for further optimizing the direct production of Vitamin C. [0010] This may be achieved by concurrent manipulation of a specific set of genes as further described herein. Such genes may be selected from the group consisting of RCS or SMS genes. This group of genes/proteins and the manip- ulation of each set is further described and exemplified herein. [0011] The term "direct fermentation", "direct production", "direct conversion" and the like is intended to mean that a 45 microorganism is capable of the conversion of a certain substrate into the specified product by means of one or more biological conversion steps, without the need of any additional chemical conversion step. For instance, the term "direct conversion of D-sorbitol into Vitamin C" is intended to describe a process wherein a microorganism is producing Vitamin C and wherein D-sorbitol is offered as a carbon source without the need of an intermediate chemical conversion step. A single microorganism capable of directly fermenting Vitamin C is preferred. 50 [0012] As used herein, "improved" or "improved yield of Vitamin C" caused by a genetic alteration means an increase of at least 5%, 10%, 25%, 30%, 40%, 50%, 75%, 100%, 200% or even more than 500%, compared to a cell which is not genetically altered. Such unaltered cells are also often referred to as wild type cells [0013] Therefore, it is in the first instance an object of the present invention to provide a process for the direct fermen- tative production of Vitamin C by cultering under suitable culture conditions a host cell which genome is genetically 55 engineered by DNA sequences comprising the following polynucleotides a) a polynucleotide encoding L-sorbosone dehydrogenase according to SEQ ID NO: 2 or an active fragment or derivative thereof, and 3 EP 2 308 965 A1 b) at least one polynucleotide encoding a protein selected from the group consisting of 1) proteins which are involved in the Sorbitol/Sorbose Metabolization System (SMS); and 2) proteins which are involved in the Respiratory Chain System (RCS); 5 and by isolation of Vitamin C from such cells or the culture medium.
Load more

Recommended publications
  • Ornithine Aminotransferase, an Important Glutamate-Metabolizing Enzyme at the Crossroads of Multiple Metabolic Pathways
    biology Review Ornithine Aminotransferase, an Important Glutamate-Metabolizing Enzyme at the Crossroads of Multiple Metabolic Pathways Antonin Ginguay 1,2, Luc Cynober 1,2,*, Emmanuel Curis 3,4,5,6 and Ioannis Nicolis 3,7 1 Clinical Chemistry, Cochin Hospital, GH HUPC, AP-HP, 75014 Paris, France; [email protected] 2 Laboratory of Biological Nutrition, EA 4466 PRETRAM, Faculté de Pharmacie, Université Paris Descartes, 75006 Paris, France 3 Laboratoire de biomathématiques, plateau iB2, Faculté de Pharmacie, Université Paris Descartes, 75006 Paris, France; [email protected] (E.C.); [email protected] (I.N.) 4 UMR 1144, INSERM, Université Paris Descartes, 75006 Paris, France 5 UMR 1144, Université Paris Descartes, 75006 Paris, France 6 Service de biostatistiques et d’informatique médicales, hôpital Saint-Louis, Assistance publique-hôpitaux de Paris, 75010 Paris, France 7 EA 4064 “Épidémiologie environnementale: Impact sanitaire des pollutions”, Faculté de Pharmacie, Université Paris Descartes, 75006 Paris, France * Correspondence: [email protected]; Tel.: +33-158-411-599 Academic Editors: Arthur J.L. Cooper and Thomas M. Jeitner Received: 26 October 2016; Accepted: 24 February 2017; Published: 6 March 2017 Abstract: Ornithine δ-aminotransferase (OAT, E.C. 2.6.1.13) catalyzes the transfer of the δ-amino group from ornithine (Orn) to α-ketoglutarate (aKG), yielding glutamate-5-semialdehyde and glutamate (Glu), and vice versa. In mammals, OAT is a mitochondrial enzyme, mainly located in the liver, intestine, brain, and kidney. In general, OAT serves to form glutamate from ornithine, with the notable exception of the intestine, where citrulline (Cit) or arginine (Arg) are end products.
    [Show full text]
  • |I|||||IIIHIII US005541.108A United States Patent (19) 11 Patent Number: 5,541,108 Fujiwara Et Al
    |I|||||IIIHIII US005541.108A United States Patent (19) 11 Patent Number: 5,541,108 Fujiwara et al. (45) Date of Patent: Jul. 30, 1996 54 GLUCONOBACTER OXYDANS STRAINS 5,082,785 l/1992. Manning et al. .................. 435/252.32 75 Inventors: Akiko Fujiwara, Kamakura; Teruhide FOREIGN PATENT DOCUMENTS Sugisawa; Masako Shinjoh, both of 994119 9/1963 United Kingdom................... 435/138 Yokohama; Yutaka Setoguchi; Tatsuo Hoshino, both of Kamakura, all of OTHER PUBLICATIONS Japan Stanbury et al. Principles of fermentation Technology, 1984, Pergamon Press. 73 Assignee: Hoffmann-La Roche Inc., Nutley, N.J. ATCC Catalogue of Bacteria, 1989, p. 106. Tsukada et al, Biotechnology and Bioengineering, vol 14, 21 Appl. No. 266,998 1972 pp. 799-810, John Wiley & Sons, Inc. Makover, et al., Biotechnology and Bioengineering XVII, 22 Filed: Jun. 28, 1994 pp. 1485-1514 (1975). Related U.S. Application Data Isono, et al. Agr. Biol. Chem, 35 No. 4 pp. 424–431 (1968). Okazaki, et al, Agr. Biol. Chem 32 No. 10 pp. 1250-1255 63 Continuation of Ser. No. 183,924, Jan. 18, 1994, abandoned, (1968). which is a continuation of Ser. No. 16,478, Feb. 10, 1993, Martin etal, Eur. S. Appl. Microbiology3, pp. 91-95 (1976). abandoned, which is a continuation of Ser. No. 517,972, Apr. Acta Microbologica Sinica 20 (3):246-251 (1980) (Abstract 30, 1990, abandoned, which is a continuation of Ser. No. only). 899,586, Aug. 25, 1986, abandoned. Acta Microbiologica Sinica 21 (2): 185-191- (1981) 30 Foreign Application Priority Data (Abstract only). Aug. 28, 1985 GB United Kingdom ................... 852359 Primary Examiner Irene Marx Jul.
    [Show full text]
  • Solarbio Catalogue with PRICES
    CAS Name Grade Purity Biochemical Reagent Biochemical Reagent 75621-03-3 C8390-1 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS Ultra Pure Grade 1g 75621-03-3 C8390-5 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonateCHAPS 5g 57-09-0 C8440-25 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 25g 57-09-0 C8440-100 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 100g 57-09-0 C8440-500 Cetyl-trimethyl Ammonium Bromide CTAB High Pure Grade ≥99.0% 500g E1170-100 0.5M EDTA (PH8.0) 100ml E1170-500 0.5M EDTA (PH8.0) 500ml 6381-92-6 E8030-100 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 100g 6381-92-6 E8030-500 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 500g 6381-92-6 E8030-1000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 1kg 6381-92-6 E8030-5000 EDTA disodium salt dihydrate EDTA Na2 Biotechnology Grade ≥99.0% 5kg 60-00-4 E8040-100 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 100g 60-00-4 E8040-500 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 500g 60-00-4 E8040-1000 Ethylenediaminetetraacetic acid EDTA Ultra Pure Grade ≥99.5% 1kg 67-42-5 E8050-5 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 5g 67-42-5 E8050-10 Ethylene glycol-bis(2-aminoethylether)-N,N,NEGTA′,N′-tetraacetic acid Ultra Pure Grade ≥97.0% 10g 50-01-1 G8070-100 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 100g 50-01-1 G8070-500 Guanidine Hydrochloride Guanidine HCl ≥98.0%(AT) 500g 56-81-5
    [Show full text]
  • Fungal Pathogenesis in Humans the Growing Threat
    Fungal Pathogenesis in Humans The Growing Threat Edited by Fernando Leal Printed Edition of the Special Issue Published in Genes www.mdpi.com/journal/genes Fungal Pathogenesis in Humans Fungal Pathogenesis in Humans The Growing Threat Special Issue Editor Fernando Leal MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editor Fernando Leal Instituto de Biolog´ıa Funcional y Genomica/Universidad´ de Salamanca Spain Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Genes (ISSN 2073-4425) from 2018 to 2019 (available at: https://www.mdpi.com/journal/genes/special issues/Fungal Pathogenesis Humans Growing Threat). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03897-900-5 (Pbk) ISBN 978-3-03897-901-2 (PDF) Cover image courtesy of Fernando Leal. c 2019 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Special Issue Editor ...................................... vii Fernando Leal Special Issue: Fungal Pathogenesis in Humans: The Growing Threat Reprinted from: Genes 2019, 10, 136, doi:10.3390/genes10020136 ..................
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Zheng Zhao, Delft University of Technology Marcel A. van den Broek, Delft University of Technology S. Aljoscha Wahl, Delft University of Technology Wilbert H. Heijne, DSM Biotechnology Center Roel A. Bovenberg, DSM Biotechnology Center Joseph J. Heijnen, Delft University of Technology An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Marco A. van den Berg, DSM Biotechnology Center Peter J.T. Verheijen, Delft University of Technology Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. PchrCyc: Penicillium rubens Wisconsin 54-1255 Cellular Overview Connections between pathways are omitted for legibility. Liang Wu, DSM Biotechnology Center Walter M. van Gulik, Delft University of Technology L-quinate phosphate a sugar a sugar a sugar a sugar multidrug multidrug a dicarboxylate phosphate a proteinogenic 2+ 2+ + met met nicotinate Mg Mg a cation a cation K + L-fucose L-fucose L-quinate L-quinate L-quinate ammonium UDP ammonium ammonium H O pro met amino acid a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar K oxaloacetate L-carnitine L-carnitine L-carnitine 2 phosphate quinic acid brain-specific hypothetical hypothetical hypothetical hypothetical
    [Show full text]
  • Expression, Purification and Characterization of a Quinoprotein L-Sorbose Dehydrogenase from Ketogulonicigenium Vulgare Y25
    Vol. 7(24), pp. 3117-3124, 11 June, 2013 DOI: 10.5897/AJMR12.2280 ISSN 1996-0808 ©2013 Academic Journals African Journal of Microbiology Research http://www.academicjournals.org/AJMR Full Length Research Paper Expression, purification and characterization of a quinoprotein L-sorbose dehydrogenase from Ketogulonicigenium vulgare Y25 Xionghua Xiong1#, Xin Ge1#, Yan Zhao2#, Xiaodong Han3, Jianhua Wang1 and Weicai Zhang1* 1Laboratory of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, China. 2Central Laboratory, The first Affiliated Hospital of Xiamen University, Xiamen 361003, China. 3College of Life Sciences, Nankai University, Tianjin 300071, China. Accepted 10 May, 2013 It is well known that Ketogulonicigenium vulgare Y25 could effectively oxidize L-sorbose to 2-keto-L- gulonic acid (2KGA), an industrial precursor of vitamin C. There in, L-sorbose dehydrogenase is one of the key enzymes responsible for the production of 2KGA. From this organism, the coding region of sdh gene was cloned into pET22b plasmid and its transcription product was overexpressed. This procedure allowed purification of L-sorbose dehydrogenase and production of polyclonal antibodies. In Western blot assays, the antibodies gave a positive reaction against bacteria protein extract and purified L- sorbose dehydrogenase. The molecular mass of the enzyme was 60532 Da, and the N-terminal amino acid sequence was determined to be QTAIT. The Native-PAGE and resting-cell reaction assay showed that purified L-sorbose dehydrogenase could convert L-sorbose to 2KGA, and PQQ was found to be indispensable for its activity as prosthetic group. The enzyme showed broad substrates specificity and the Km value for L-sorbose and 1-propanol was 21.9 mM and 0.13 mM, respectively.
    [Show full text]
  • Establishing an Innovative Carbohydrate Metabolic Pathway For
    Wang et al. Microb Cell Fact (2018) 17:81 https://doi.org/10.1186/s12934-018-0932-9 Microbial Cell Factories RESEARCH Open Access Establishing an innovative carbohydrate metabolic pathway for efcient production of 2‑keto‑L‑gulonic acid in Ketogulonicigenium robustum initiated by intronic promoters Cai‑Yun Wang1, Ye Li1,2, Zi‑Wei Gao3, Li‑Cheng Liu1, Meng‑Yue Zhang1, Tian‑Yuan Zhang1, Chun‑Fu Wu1 and Yi‑Xuan Zhang1* Abstract Background: 2-Keto-L-gulonic acid (2-KGA), the precursor of vitamin C, is currently produced by two-step fermenta‑ tion. In the second step, L-sorbose is transformed into 2-KGA by the symbiosis system composed of Ketogulonicige- nium vulgare and Bacillus megaterium. Due to the diferent nutrient requirements and the uncertain ratio of the two strains, the symbiosis system signifcantly limits strain improvement and fermentation optimization. Results: In this study, Ketogulonicigenium robustum SPU_B003 was reported for its capability to grow well indepen‑ dently and to produce more 2-KGA than that of K. vulgare in a mono-culture system. The complete genome of K. robustum SPU_B003 was sequenced, and the metabolic characteristics were analyzed. Compared to the four reported K. vulgare genomes, K. robustum SPU_B003 contained more tRNAs, rRNAs, NAD and NADP biosynthetic genes, as well as regulation- and cell signaling-related genes. Moreover, the amino acid biosynthesis pathways were more complete. Two species-specifc internal promoters, P1 (orf_01408 promoter) and P2 (orf_02221 promoter), were predicted and validated by detecting their initiation activity. To efciently produce 2-KGA with decreased ­CO2 release, an innovative acetyl-CoA biosynthetic pathway (XFP-PTA pathway) was introduced into K.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Enzyme Classification
    1st Proof 29-7-08 + 0)26-4 ENZYME CLASSIFICATION 2.1 INTRODUCTION 2.1.1 Enzymes Enzymes are biological catalysts that increase the rate of chemical reactions by lowering the activation energy. The molecules involved in the enzyme mediated reactions are known as substrates and the outcome of the reaction or yield is termed product. Generally, the chemical nature of most of the enzymes are proteins and rarely of other types (e.g., RNA). The enzymes are too specific towards their substrates to which they react and thereby the reaction will also be so specific. Sometimes the enzyme needs the presence of a non-protein component (co-enzyme, if it is a vitamin derived organic compound or co-factor, if it is a metal ion) for accomplishing the reaction. In this case, the whole enzyme may be called a holoenzyme, the protein part as apoenzyme and the non-protein constituent a prosthetic group. 2.1.2 Enzyme Nomenclature Principles The sixth complete edition of Enzyme Nomenclature, was published under the patronage of the International Union of Biochemistry and Molecular Biology (formerly the International Union of Biochemistry). By the late 1950s it had become evident that the nomenclature of enzymology was not following the guidelines formulated owing to an increase in the number of enzymes. The naming of enzymes by individual workers had proved far from satisfactory in practice. In many cases the same enzymes were known by several different names, while conversely the same name was sometimes coined to different enzymes. Many of the names conveyed little or no idea about the nature of the reactions catalyzed.
    [Show full text]
  • Supplementary Material (ESI) for Natural Product Reports
    Electronic Supplementary Material (ESI) for Natural Product Reports. This journal is © The Royal Society of Chemistry 2014 Supplement to the paper of Alexey A. Lagunin, Rajesh K. Goel, Dinesh Y. Gawande, Priynka Pahwa, Tatyana A. Gloriozova, Alexander V. Dmitriev, Sergey M. Ivanov, Anastassia V. Rudik, Varvara I. Konova, Pavel V. Pogodin, Dmitry S. Druzhilovsky and Vladimir V. Poroikov “Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review” Contents PASS (Prediction of Activity Spectra for Substances) Approach S-1 Table S1. The lists of 122 known therapeutic effects for 50 analyzed medicinal plants with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-6 Table S2. The lists of 3,345 mechanisms of action that were predicted by PASS and were used in this study with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-9 Table S3. Comparison of direct PASS prediction results of known effects for phytoconstituents of 50 TIM plants with prediction of known effects through “mechanism-effect” and “target-pathway- effect” relationships from PharmaExpert S-79 S-1 PASS (Prediction of Activity Spectra for Substances) Approach PASS provides simultaneous predictions of many types of biological activity (activity spectrum) based on the structure of drug-like compounds. The approach used in PASS is based on the suggestion that biological activity of any drug-like compound is a function of its structure.
    [Show full text]
  • Springer Handbook of Enzymes
    Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes Alphabetical Name Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2010 This work is subject to copyright. All rights reserved, whether in whole or part of the material con- cerned, specifically the right of translation, printing and reprinting, reproduction and storage in data- bases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–7, Name Index 2.4.1.60 abequosyltransferase, Vol. 31, p. 468 2.7.1.157 N-acetylgalactosamine kinase, Vol. S2, p. 268 4.2.3.18 abietadiene synthase, Vol. S7,p.276 3.1.6.12 N-acetylgalactosamine-4-sulfatase, Vol. 11, p. 300 1.14.13.93 (+)-abscisic acid 8’-hydroxylase, Vol. S1, p. 602 3.1.6.4 N-acetylgalactosamine-6-sulfatase, Vol. 11, p. 267 1.2.3.14 abscisic-aldehyde oxidase, Vol. S1, p. 176 3.2.1.49 a-N-acetylgalactosaminidase, Vol. 13,p.10 1.2.1.10 acetaldehyde dehydrogenase (acetylating), Vol. 20, 3.2.1.53 b-N-acetylgalactosaminidase, Vol. 13,p.91 p. 115 2.4.99.3 a-N-acetylgalactosaminide a-2,6-sialyltransferase, 3.5.1.63 4-acetamidobutyrate deacetylase, Vol. 14,p.528 Vol. 33,p.335 3.5.1.51 4-acetamidobutyryl-CoA deacetylase, Vol. 14, 2.4.1.147 acetylgalactosaminyl-O-glycosyl-glycoprotein b- p. 482 1,3-N-acetylglucosaminyltransferase, Vol. 32, 3.5.1.29 2-(acetamidomethylene)succinate hydrolase, p. 287 Vol.
    [Show full text]
  • Comprehensive Metabolomic Study of the Response of HK-2 Cells to Hyperglycemic, Hypoxic Diabetic-Like Milieu Has Never Been Performed
    www.nature.com/scientificreports OPEN Comprehensive metabolomic study of the response of HK‑2 cells to hyperglycemic hypoxic diabetic‑like milieu Alberto Valdés 1,2*, Francisco J. Lucio‑Cazaña3, María Castro‑Puyana1,4, Coral García‑Pastor3, Oliver Fiehn2 & María Luisa Marina 1,4* Diabetic nephropathy (DN) is the leading cause of chronic kidney disease. Although hyperglycaemia has been determined as the most important risk factor, hypoxia also plays a relevant role in the development of this disease. In this work, a comprehensive metabolomic study of the response of HK‑2 cells, a human cell line derived from normal proximal tubular epithelial cells, to hyperglycemic, hypoxic diabetic‑like milieu has been performed. Cells simultaneously exposed to high glucose (25 mM) and hypoxia (1% O2) were compared to cells in control conditions (5.5 mM glucose/18.6% O2) at 48 h. The combination of advanced metabolomic platforms (GC‑TOF MS, HILIC‑ and CSH‑ QExactive MS/MS), freely available metabolite annotation tools, novel databases and libraries, and stringent cut‑of flters allowed the annotation of 733 metabolites intracellularly and 290 compounds in the extracellular medium. Advanced bioinformatics and statistical tools demonstrated that several pathways were signifcantly altered, including carbohydrate and pentose phosphate pathways, as well as arginine and proline metabolism. Other afected metabolites were found in purine and lipid metabolism, the protection against the osmotic stress and the prevention of the activation of the β‑oxidation pathway. Overall, the efects of the combined exposure of HK‑cells to high glucose and hypoxia are reasonably compatible with previous in vivo works. Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and if afects approximately 25–40% of type 1 and type 2 diabetic patients 1,2.
    [Show full text]